Skip to main content
Erschienen in: Clinical and Translational Oncology 8/2017

02.03.2017 | Review Article

The potential role of brachytherapy in the irradiation of patients with lung cancer: a systematic review

verfasst von: A. Youroukou, I. Gkiozos, Z. Kalaitzi, I. Tsalafoutas, K. Papalla, A. Charpidou, V. Kouloulias

Erschienen in: Clinical and Translational Oncology | Ausgabe 8/2017

Einloggen, um Zugang zu erhalten

Abstract

To review the use of brachytherapy as an adjuvant therapy to reduce recurrences after sublobar resections and as a palliation to patients with inoperable disease. Α review of all published studies was performed to identify the recurrence rate after brachytherapy adjuvant to sublobar resection and assess the palliation of symptoms and the complications of brachytherapy as a palliative treatment. Most of the studies that we found about brachytherapy as an adjuvant therapy to sublobar resection due to patient’s poor cardiopulmonary reserve showed that brachytherapy offered low recurrence rate with low toxicity. Ten studies concerning palliative brachytherapy showed improvement of symptoms with good tolerance and good endoscopic response rates. Literature suggests that brachytherapy for inoperable symptomatic disease can be delivered for symptom improvement with acceptable toxicity. Brachytherapy as an alternative treatment option for lung cancer needs more investigation with more prospective trials.
Literatur
1.
Zurück zum Zitat Gunderson LL, Tepper JE. Clinical radiation oncology. 3rd ed. Amsterdam: Elsevier; 2012. p. 783. Gunderson LL, Tepper JE. Clinical radiation oncology. 3rd ed. Amsterdam: Elsevier; 2012. p. 783.
2.
Zurück zum Zitat Halperin EC, Brady LW, Wazer DE, Perez CA. Perez and Brady’s: principles and practice of radiation oncology. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2013. p. 1308. Halperin EC, Brady LW, Wazer DE, Perez CA. Perez and Brady’s: principles and practice of radiation oncology. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2013. p. 1308.
3.
Zurück zum Zitat Fay M, Poole CM, Pratt G. Recent advances in radiotherapy for thoracic tumours. J Thorac Dis. 2013;5(Suppl 5):S551–5.PubMedPubMedCentral Fay M, Poole CM, Pratt G. Recent advances in radiotherapy for thoracic tumours. J Thorac Dis. 2013;5(Suppl 5):S551–5.PubMedPubMedCentral
4.
Zurück zum Zitat Santos R, Colonias A, Parda D, Trombetta M, Maley RH, Macherey R, et al. Comparison between sublobar resection and 125Iodine brachytherapy after sublobar resection in high-risk patients with Stage I non-small-cell lung cancer. Surgery. 2003;134(4):691–7.CrossRef Santos R, Colonias A, Parda D, Trombetta M, Maley RH, Macherey R, et al. Comparison between sublobar resection and 125Iodine brachytherapy after sublobar resection in high-risk patients with Stage I non-small-cell lung cancer. Surgery. 2003;134(4):691–7.CrossRef
5.
Zurück zum Zitat Landreneau JP, Schuchert MJ, Weyant R, Abbas G, Wizorek JJ, Awais O, et al. Anatomic segmentectomy and brachytherapy mesh implantation for clinical stage I non-small cell lung cancer (NSCLC). Surgery. 2014;155(2):340–6.CrossRef Landreneau JP, Schuchert MJ, Weyant R, Abbas G, Wizorek JJ, Awais O, et al. Anatomic segmentectomy and brachytherapy mesh implantation for clinical stage I non-small cell lung cancer (NSCLC). Surgery. 2014;155(2):340–6.CrossRef
6.
Zurück zum Zitat Voynov G, Heron DE, Lin CJ, Burton S, Chen A, Quinn A, et al. Intraoperative (125)I Vicryl mesh brachytherapy after sublobar resection for high-risk stage I non-small cell lung cancer. Brachytherapy. 2005;4(4):278–85.CrossRef Voynov G, Heron DE, Lin CJ, Burton S, Chen A, Quinn A, et al. Intraoperative (125)I Vicryl mesh brachytherapy after sublobar resection for high-risk stage I non-small cell lung cancer. Brachytherapy. 2005;4(4):278–85.CrossRef
7.
Zurück zum Zitat Fernando HC, Landreneau RJ, Mandrekar SJ, Nichols FC, Hillman SL, Heron DE, et al. Impact of brachytherapy on local recurrence rates after sublobar resection: results from ACOSOG Z4032 (Alliance), a phase III randomized trial for high-risk operable non-small-cell lung cancer. J Clin Oncol. 2014;32:2456–62.CrossRef Fernando HC, Landreneau RJ, Mandrekar SJ, Nichols FC, Hillman SL, Heron DE, et al. Impact of brachytherapy on local recurrence rates after sublobar resection: results from ACOSOG Z4032 (Alliance), a phase III randomized trial for high-risk operable non-small-cell lung cancer. J Clin Oncol. 2014;32:2456–62.CrossRef
8.
Zurück zum Zitat Chen A, Galloway M, Landreneau R, d’Amato T, Colonias A, Karlovits S, et al. Intraoperative 125I brachytherapy for high-risk stage I non-small cell lung carcinoma. Int J Radiat Oncol Biol Phys. 1999;44(5):1057–63.CrossRef Chen A, Galloway M, Landreneau R, d’Amato T, Colonias A, Karlovits S, et al. Intraoperative 125I brachytherapy for high-risk stage I non-small cell lung carcinoma. Int J Radiat Oncol Biol Phys. 1999;44(5):1057–63.CrossRef
9.
Zurück zum Zitat Colonias A, Betler J, Trombetta M, Bigdeli G, Gayou O, Keenan R, et al. Mature follow-up for high-risk stage I non-small-cell lung carcinoma treated with sublobar resection and intraoperative iodine-125 brachytherapy. Int J Radiat Oncol Biol Phys. 2011;79(1):105–9.CrossRef Colonias A, Betler J, Trombetta M, Bigdeli G, Gayou O, Keenan R, et al. Mature follow-up for high-risk stage I non-small-cell lung carcinoma treated with sublobar resection and intraoperative iodine-125 brachytherapy. Int J Radiat Oncol Biol Phys. 2011;79(1):105–9.CrossRef
10.
Zurück zum Zitat Tselis N, Ferentinos K, Kolotas C, Schirren J, Baltas D, Antonakakis A, et al. Computed tomography-guided interstitial high-dose-rate brachytherapy in the local treatment of primary and secondary intrathoracic malignancies. J Thorac Oncol. 2011;6:545–52.CrossRef Tselis N, Ferentinos K, Kolotas C, Schirren J, Baltas D, Antonakakis A, et al. Computed tomography-guided interstitial high-dose-rate brachytherapy in the local treatment of primary and secondary intrathoracic malignancies. J Thorac Oncol. 2011;6:545–52.CrossRef
11.
Zurück zum Zitat Huang Q, Chen J, Chen Q, Lai Q, Cai S, Luo K, et al. Computed tomographic-guided iodine-125 interstitial implants for malignant thoracic tumors. Eur J Radiol. 2013;82(11):2061–6.CrossRef Huang Q, Chen J, Chen Q, Lai Q, Cai S, Luo K, et al. Computed tomographic-guided iodine-125 interstitial implants for malignant thoracic tumors. Eur J Radiol. 2013;82(11):2061–6.CrossRef
12.
Zurück zum Zitat Zorlu AF, Selek U, Emri S, Gurkaynak M, Akyol FH. Second line palliative endobronchial radiotherapy with HDR Ir 192 in recurrent lung carcinoma. Yonsei Med J. 2008;49(4):620–4.CrossRef Zorlu AF, Selek U, Emri S, Gurkaynak M, Akyol FH. Second line palliative endobronchial radiotherapy with HDR Ir 192 in recurrent lung carcinoma. Yonsei Med J. 2008;49(4):620–4.CrossRef
13.
Zurück zum Zitat Escobar-Sacristán JA, Granda-Orive JI, Gutiérrez Jiménez T, Delgado JM, Rodero Baños A, Saez Valls R. Endobronchial brachytherapy in the treatment of malignant lung tumours. Eur Respir J. 2004;24(3):348–52.CrossRef Escobar-Sacristán JA, Granda-Orive JI, Gutiérrez Jiménez T, Delgado JM, Rodero Baños A, Saez Valls R. Endobronchial brachytherapy in the treatment of malignant lung tumours. Eur Respir J. 2004;24(3):348–52.CrossRef
14.
Zurück zum Zitat Kelly JF, Delclos ME, Morice RC, Huaringa A, Allen PK, Komaki R. High-dose-rate endobronchial brachytherapy effectively palliates symptoms due to airway tumors: the 10-year M. D. Anderson cancer center experience. Int J Radiat Oncol Biol Phys. 2000;48(3):697–702.CrossRef Kelly JF, Delclos ME, Morice RC, Huaringa A, Allen PK, Komaki R. High-dose-rate endobronchial brachytherapy effectively palliates symptoms due to airway tumors: the 10-year M. D. Anderson cancer center experience. Int J Radiat Oncol Biol Phys. 2000;48(3):697–702.CrossRef
15.
Zurück zum Zitat Celebioglu B, Gurkan OU, Erdogan S, Savas I, Köse K, Kurtman C, et al. High dose rate endobronchial brachytherapy effectively palliates symptoms due to inoperable lung cancer. Jpn J Clin Oncol. 2002;32(11):443–8.CrossRef Celebioglu B, Gurkan OU, Erdogan S, Savas I, Köse K, Kurtman C, et al. High dose rate endobronchial brachytherapy effectively palliates symptoms due to inoperable lung cancer. Jpn J Clin Oncol. 2002;32(11):443–8.CrossRef
16.
Zurück zum Zitat Macha HN, Wahlers B, Reichle C, von Zwehl D. Endobronchial radiation therapy for obstructing malignancies: ten years’ experience with iridium-192high-dose radiation brachytherapy afterloading technique in 365 patients. Lung. 1995;173(5):271–80.CrossRef Macha HN, Wahlers B, Reichle C, von Zwehl D. Endobronchial radiation therapy for obstructing malignancies: ten years’ experience with iridium-192high-dose radiation brachytherapy afterloading technique in 365 patients. Lung. 1995;173(5):271–80.CrossRef
17.
Zurück zum Zitat Guarnaschelli JN, Jose BO. Palliative high-dose-rate endobronchial brachytherapy for recurrent carcinoma: the University of Louisville experience. J Palliat Med. 2010;13(8):981–9.CrossRef Guarnaschelli JN, Jose BO. Palliative high-dose-rate endobronchial brachytherapy for recurrent carcinoma: the University of Louisville experience. J Palliat Med. 2010;13(8):981–9.CrossRef
18.
Zurück zum Zitat de Aquino Gorayeb MM, Gregório MG, de Oliveira EQ, Aisen S, Carvalho Hde A. High-dose-rate brachytherapy in symptom palliation due to malignant endobronchial obstruction: a quantitative assessment. Brachytherapy. 2013;12(5):471–8.CrossRef de Aquino Gorayeb MM, Gregório MG, de Oliveira EQ, Aisen S, Carvalho Hde A. High-dose-rate brachytherapy in symptom palliation due to malignant endobronchial obstruction: a quantitative assessment. Brachytherapy. 2013;12(5):471–8.CrossRef
19.
Zurück zum Zitat Aumont-Le Guilcher M, Prevost B, Sunyach P, Pieffert D, Maingon P, Thomas L, et al. High-dose-rate brachytherapy for non-small-cell lung carcinoma: a retrospective study of 226 patients. Int J Rad Oncol Biol Phys. 2011;79:1112–6.CrossRef Aumont-Le Guilcher M, Prevost B, Sunyach P, Pieffert D, Maingon P, Thomas L, et al. High-dose-rate brachytherapy for non-small-cell lung carcinoma: a retrospective study of 226 patients. Int J Rad Oncol Biol Phys. 2011;79:1112–6.CrossRef
Metadaten
Titel
The potential role of brachytherapy in the irradiation of patients with lung cancer: a systematic review
verfasst von
A. Youroukou
I. Gkiozos
Z. Kalaitzi
I. Tsalafoutas
K. Papalla
A. Charpidou
V. Kouloulias
Publikationsdatum
02.03.2017
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology / Ausgabe 8/2017
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-017-1635-0

Weitere Artikel der Ausgabe 8/2017

Clinical and Translational Oncology 8/2017 Zur Ausgabe

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.